SCM LifeScience Co

SCM LifeScience Co Debt Growth

The Year-over-Year Debt Growth of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is -13.85 %. In the previous year, Year-over-Year Debt Growth was -35.40 % — a change of -60.88% (higher).

Debt Growth

-13.85 %

YoY

-60.88%

Last updated:

Year-over-Year Debt Growth of SCM LifeScience Co is 2024 -13.85 % . Year-over-Year Debt Growth of SCM LifeScience Co was 2023 -35.40 % . It decreases by -60.88% higher compared to the previous year.

The SCM LifeScience Co Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
190.36 KRW
Jan 1, 2019
-71.62 KRW
Jan 1, 2020
-6.06 KRW
Jan 1, 2021
-98.69 KRW
Jan 1, 2022
6,935.77 KRW
Jan 1, 2023
-35.40 KRW
Jan 1, 2024
-13.85 KRW
The SCM LifeScience Co Debt Growth history
YEARDebt GrowthYoY
-13.85 %-60.88%
-35.40 %-100.51%
6,935.77 %-7,127.89%
-98.69 %+1,527.76%
-6.06 %-91.54%
-71.62 %-137.63%
190.36 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Year-over-Year Debt Growth of SCM LifeScience Co is -13.85 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's SCM LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co